Company Profile

SHAL Technologies is currently focused on the development of a series of small molecule diagnostics and therapeutics for treating non-Hodgkin's lymphoma and other types of B-cell lymphoma. The company's Selective High Affinity Ligands (SHALs) represent a new class of small molecule targeting agents (<5,000 Da) with superior characteristics surpassing those of monoclonal antibodies (mAbs) and antibody fragments and other small molecule targeted therapeutics currently available or reported in the pipeline for the treatment of non-Hodgkin’s lymphoma (NHL). SHALs can be designed to bind selectively and with high (nM to pM) affinity to unique sites located on any structured protein. The firm developed a modular approach for the synthesis of SHALs in which two or three ligand “recognition elements” (ligands predicted by docking to bind to specific sites on proteins and experimentally confirmed to bind) are conjugated to the ends of a linker scaff